M. Bharmal

Abstract B058: Combining RAS and splicing inhibition in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancer types in the United States, with over 90% of tumors driven by oncogenic KRAS. Several KRAS inhibitors have demonstrated promising preclinical or early clinical efficacy; however, their therapeutic benefit is limited by the emergence of acquired...